W e undertook a study to determine the specificity of the monoclonal antibody, B-ly-7, for hairy cell leukemia (HCL) by examining the expression in 150 samples from B-cell lymphoproliferative diseases as well as screening for reactivity in a number of other hematologic malignancies. Within the B-cell lineage w e found that the expression of B-ly-7 was highly specific for HCL and reacted with all 28 cases examined, as well as with 3 of 9 cases of a variant form of HCL. Cells of other closely related 6-cell disorders, prolymphocytic leukemia, and splenic lymphoma with villous lymphocytes were negative. Investigation of the peripheral blood and bone marrow of patients with HCL before and after treatment with a-interferon or deoxycoformycin suggests that B-ly-7 may be useful in the assessment of minimal disease after therapy. In addition to HCL, w e found NUMBER OF monoclonal antibodies (MoAbs) have A been described that have relative specificity for hairy cell leukemia (HCL),'.2 and these include CD25 ( a n t i -T a~) ,~ CDI IC ( L~u -M~) ,~ and HC-2.5 Such antibodies are finding increased application in the diagnosis of HCL and for the detection of residual disease after treatmenL6 B -l~-7~ is an MoAb recently reported to react with HCL, but not with other lymphoid malignancies, and with a very small (0.3%) fraction of peripheral blood B cells. The MoAb was not cluster-designated at the 1989 Leucocyte Typing Conference, but recent findings have identified other MoAbs that may have similar
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The original analysis with B-ly-7 included a large number of lymphomas and other lymphoproliferative diseases, but did not include diseases that are very closely allied to HCL," such as HCL variant (HCL-V)," prolymphocytic leukemia (PLL),I3 and splenic lymphoma with villous lymphocytes (SLVL). I4 We have analyzed a significant number of cases in each of these groups to determine the specificity of B-ly-7 and its value in the diagnosis of HCL and the classification of B-cell disorders, and also to determine whether this antibody may be of value in the assessment of HCL after therapy with cu-interferon and deoxycoformycin. In addition, we screened a number of T-cell malignancies that had not been previously studied to examine whether reactivity with B-ly-7 was found in these disorders. Finally, we examined in vitro activated B cells and T cells from tonsil and peripheral blood to test the hypothesis that the B-ly-7 reactive antigen might be an activation antigen on lymphoid cells.
MATERIALS AND METHODS
B-ly-7 was produced by Dr Sibrand Poppema (Cross Cancer Institute, Edmonton, Canada).' HC-2 was a gift from Dr D. Posnett (Cornell University, New York, NY). CD3 (Leu-4), CD4 (Leu-3), CD5 (Leu]), CD8 (Leu-Za), CD1 IC (Leu-MS), CD19 (LeulZ), CD20 (Leu-16), and CD25 (anti-IL-2R) were from Becton Dickinson UK (Oxford). CD23 (MHM6) was a gift from Professor A. McMichael (Oxford) and Dr D. Crawford (London, UK), and anti-HLA-DR (GRB-1) was from Professor F. Garrido (Granada). Ki-67 was from Dako (High Wycombe, UK), and CD22 (OKB22) and CD38 (OKT-IO) were from Ortho (Raritan, NJ).
Antibodies.
that B-ly-7 was positive with cells of three mature, CD4' T-cell malignancies. In view of the reactivity with malignancies of activated B and T cells, we searched for the expression of 6-ly-7 on activated, normal B and T cells and found that B-ly-7 reacted specifically with activated normal peripheral blood CD8' T cells. 6-ly-7 has a number of applications, including the precise classification of mature B-cell neoplasia and the diagnosis HCL and its assessment after treatment. In addition, B-ly-7 recognizes a small subset of T-cell disorders. Its expression on these malignancies and on in vitro activated peripheral blood CD8' T cells suggests that B-ly-7 detects a lymphocyte activation antigen. 0 1990 by The American Society of Hematology.
Tissues. Peripheral blood or bone marrow mononuclear cells were separated on a density gradient with Lymphoprep (Nycomed, Oslo, Norway) and washed twice. Single cell suspensions were prepared from tonsil by finely mincing the tissue, sieving, and separation of mononuclear cells on a density gradient.
Cells were suspended at 2 x 107/mL in cold phosphate-buffered saline (PBS) containing 0.02% (wt/vol) sodium azide (NaN,) and 2% AB serum. Aliquots of 100 jtL were incubated at 4OC (on ice) for 30 minutes either directly with FITC-, phycoerythrin (PE)-, or rhodamine (RD)-conjugated antibody, or with unlabeled murine MoAb followed by 100 jtL of a 1:20 dilution of FITC-conjugated anti-mouse antiserum (Cappell, West Chester, PA). Two-color immunofluorescence with B-ly-7 was achieved by incubation with B-ly-7 followed by FITC-conjugated second layer, then addition of excess normal mouse immunoglobulin to block free binding sites. A second PE-or RD-conjugated MoAb was then added for red staining. Controls were used for each step to demonstrate specificity. Stained cells were excited by an argon laser with peak intensity at 488 nm, and analyzed for green and red fluorescence on log scale using a FACS Scan flow cytometer (Becton Dickinson, Mountain View, CA). "FACS Scan Research" software was also used for analysis. The degree of positivity was assessed by comparison with controls and expressed as a "percentage" by the placement of an arbitrary electronic gate.
The alkaline phosphatase anti-alkaline phosphatase method (APAAP) was applied on cytospin-made slides and frozen sections of bone marrow trephines. Studies had indicated that B-ly-7 did not stain paraffin embedded sections. Briefly, slides stored at -2OOC wrapped in foil were allowed to thaw, fixed in pure acetone, and dried. Diluted MoAbs were added for 30 minutes, and then sequentially incubated with a rabbit anti-mouse serum (Dako) for 30 minutes and with the APAAP complexes (Dako) for 45 minutes. After incubation with the alkaline phosphatase substrate for 15 to 20 minutes, the slides were counterstained with Harris hematoxylin for 10 to 20 seconds.
Tissue culture was performed in RPMI 1640 medium (GIBCO, Grand Island, NY) supplemented with HEPES (4.76 g/L), bicarbonate (0.85 g/L), and antibiotics (penicillin 100 IU/mL and streptomycin 100 pg/mL) (BDH Chemicals, Poole, UK) with 10% fetal calf serum (FCS; Flow) (vol/vol) in sterile 50-cm2 tissue culture flasks (Nunc) and incubated in 5% CO, in air at 37OC and 100% humidity. 2-Aminoethylisothiouronium bromide (AET) (Sigma, Poole, UK) treated sheep red blood cells (SRBC) were prepared using 20 mL of freshly prepared 2% (wt/vol) AET solution added to 5 mL packed SRBC, and incubating for 15 minutes at 37OC. The SRBC were washed five times and a 10% AET-SRBC stock solution was prepared.
Mononuclear cells (MNC) were fractionated into SRBC rosetting (E+) T cells and non-SRBC rosetting (E-) B cells. Two milliliters of 10% AET-SRBC was added to 8 x lo7 MNC, made up to 40 mL with RPMI, incubated for 5 minutes at 2OoC, layered over Lymphoprep, and centrifuged at 800gfor 20 minutes. The E-cells at the interface were harvested and the E+ cells were pelleted to the bottom of the tube with the SRBC, which were lysed using ammonium chloride erythrocyte lysis buffer. Panning for adherent cell (monocyte) depletion was performed with E-cells by placing 3 x lo7 cells in FCS/RPMI in a panning Petri dish for 2 hours at 37OC.
Cell cultures were set up by resuspending 5 x lo6 cells/mL in 10% FCS/RPMI. E-cells were cultured alone or with either 12-0-tetradecanoyl-phorbol 13-acetate (TPA) (Sigma) at 10 ng/mL, or Epstein-Barr virus (EBV) containing supernatant from a 7-day culture of B95-8 cell line (1:50). E+ cells were cultured alone or with phytohaemagglutinin (PHA), 0.05 pg/mL. Cell phenotype was assessed on days 0, 1,3, and 5.
T-and B-cell separation and in vitro activation.
RESULTS

B-cell lymphoproliferative disease.
Samples of 150 B-cell lymphoproliferative diseases" were assessed for the expression of the B-ly-7 antigen (see Table 1 ). Forty-seven B-cell malignancies were analyzed by FACS analysis and 107 by APAAP on cytospins preparations.
All 28 cases of HCL examined were positive for the B-ly-7 defined antigen irrespective of whether analysis was of membrane expression (FACS) or cytoplasmic antigen (cytospin slides). The antibody provides relatively intense staining of the hairy cells in peripheral blood, bone marrow, and spleen with both techniques. In our hands, immunofluorescense and flow cytometric analysis gave slightly more intense staining than APAAP, although the latter has the advantage of allowing morphologic assessment of the positive cells. B-ly-7 stains hairy cells with an intensity comparable with CD25, CD1 IC, and HC-2.
The reactivity of B-ly-7 in diseases that are closely associated with HCL was as follows: 3 of 9 cases of HCL-V were positive; all cases of prolymphocytic leukemia and SLVL were negative (Table 1) . Similar results were found by both flow cytometry and staining of cytocentrifuge preparations by APAAP. The fluorescence intensity of B-ly-7 by FACS analysis was similar in both HCL-V (positive cases) and HCL, with mean fluorescence intensity in channel numbers of 545 and 550, respectively.
Assessment of HCL after treatment with a-interferon (IFN) and deoxycoformycin (DCF). Samples from blood and frozen bone marrow trephine sections from 10 patients were examined. The results are shown in Table 2 . Three patients had undergone splenectomy and all had received IFN therapy in the past with complete or partial response. All patients had subsequently relapsed and then received DCF (4 mg/m2 weekly for 4 weeks followed by 2 weekly until maximal response) for a median of eight (range 3 to 15) injections. Samples were examined from eight patients who had been considered to be in complete remission after receiving DCF for a median of 4 months (range 1 to 28 months), from a patient in partial remission for 41 months, and from a patient still on therapy.
Blood and bone marrow from the patient in partial remission and from the patient still on therapy displayed hairy cells recognizable by standard morphologic criteria, and these reacted with CD25, C D l l c , HC-2, CD22, and B-ly-7. There was a good correlation between the number of B-ly-7 positive cells and the number of hairy cells identifiable by the other MoAbs (Table 2) .
Eight patients were in complete remission with normal blood counts, including monocytes and the absence of hairy cells. Histologic examination of bone marrow did not show infiltration. However, in three of these cases residual infiltration was found by cells reacting with CD25, CD1 IC, HC-2, CD22, and B-ly-7. These three patients had received 4 or 5 injections of DCF and had been considered to be in remission for 1, 2, and 28 months, respectively. Residual infiltration was not detectable in the bone marrow of the other five For patients who had received more than eight injections of DCF (8 to 15) and were considered in complete remission for 1 to 25 months after completion of DCF therapy. Fifty-one T-cell malignancies were examined, 22 cases by FACS and 29 by APAAP (see Table 1 ). This screening unexpectedly demonstrated three cases; one adult T-cell leukemia/lymphoma (ATLL), one T-cell non-Hodgkin's lymphoma (T-NHL), and one SCzary syndrome positive with B-ly-7. The ATLL showed the characteristic morphology of these cells and had the following phenotype: CD3+, CD4+, CD5+, CD25+, CDI-, CD2-, CD7-, CD8-, CD16-. The phenotype of the T-NHL was as follows: CD2+, CD4+, CD8+, CD7+, HLA-DR', CDI-, CD3-(membrane and cytoplasmic), C D Y , CD57-(Leu-7), CD16-.
The demonstration of B-ly-7 positivity in cases of both Band T-cell malignancies that are characteristic of activated cells (HCL and ATLL) prompted us to search for the
T-cell lymphoproliferative diseases.
expression of the B-ly-7 antigen in normal, activated B and T cells.
E-separated, adherent cell-depleted, tonsillar cells contained over 95% B cells assessed by CD19, with a T-cell (CD3) contamination of 2.3% and 4.9% in each of two different tonsils. Assessment on days 0, 1, 3, and 5 for the expression of B-ly-7 as well as several activation antigens showed that they did not express B-ly-7 during the course of culture, but expression of CD23, CD71 (transferrin receptor), and upregulation of HLA-DR expression was observed, indicating that B-cell activation occurred in c~l t u r e . '~ Peripheral blood MNC stimulated with PHA acquired B-ly-7 expression on days 3 and 5 of culture. The B-ly-7 positive cells also displayed CD25 (IL-2R) and HLA-DR (Table 3 and Fig 1) . The expression of B-ly-7 occurred late and was maximal on day 5 , while CD25 was present early after stimulation (day 1). Cells from the PHA culture expressed the nuclear proliferation antigen B-cell activation.
T-cell activation. As B-ly-7 cells constituted only a subset of the activated cells from peripheral blood on PHA stimulation, two-color immunofluorescence was used to define the phenotype of the B-ly-7 cells. The results are shown in Fig 2 and demonstrated that the B-ly-7 cells formed a subset of CD2+ and CD25' cells. The B-ly-7+ cells were also CD3+. However, this B-ly-7+ subset was restricted to CD8+ cells, while the CD4+ cells and B-ly-7+ cells were mutually exclusive. This indicated that the antigen detected by B-ly-7 on PHA-stimulated peripheral blood M N C was an activation antigen on CD8+ T lymphocytes. M N C from a patient with infectious mononucleosis with raised numbers of CD8' cells did not express the B-ly-7 antigen, but these cells also lacked CD25.
DISCUSSION
We have shown that the antigen recognized by B-ly-7, which is relatively specific for HCL within the B-cell disorders, is slightly more widely distributed than first described' and also is present on some T-cell malignancies, which included a case of ATLL. As both HCL and ATLL are diseases characteristic of activated cells in their respective lineages,'," we tested the hypothesis that B-ly-7 may represent an activation antigen on lymphoid cells. Although we were unable to demonstrate the antigen on in vitro stimulated purified tonsillar T or B cells, the antigen was demonstrable on a subset of normal peripheral blood T cells (CD8+) after in vitro stimulation with PHA.
In terms of the distribution of the antigen within B-cell disorders, our results confirm the restricted nature of the antigen with the reactivity confined to HCL and a proportion of cases of HCL-V. Other closely related B-cell malignancies such as PLL and SLVL did not express the B-ly-7 antigen. The expression of B-ly-7 in some HCL-V suggests that the relationship between HCL and HCL-V is close while PLL and SLVL are somewhat further removed from this stage of differentiation. HCL-V cells also usually express CDl IC, as do HCL cells, but not other HCL-related antigens such as CD25 or HC-2.I2 Hence, in terms of the specificity of B-ly-7 within the spectrum of B-cell neoplasia, B-ly-7 is more specific for HCL than is CD22, while CD1 IC in our experience is also reactive in cases of HCL-V and SLVL; CD25 and HC-2 in this context are equally specific for HCL.
The B-ly-7 antibody identifies hairy cells in the peripheral blood and bone marrow of patients with HCL, and the number of cells positive with the marker bears a close relationship with the number of morphologically recognizable hairy cells. The bone marrow trephine sections from 10 patients with HCL after treatment with DCF were analyzed in a pilot study to assess the contribution of B-ly-7 as an adjunct to histology and immunohistology with other markers in the definition of residual disease ( Table 2) . We demonstrated that B-ly-7 has the ability to detect hairy cells based on a good correlation between B-ly-7 reactivity and the presence of morphologically identifiable hairy cells, as well as a good correlation with other markers, ie, CD25, C D l l c , HC-2, and CD22. The assessment of HCL marrow histology a t diagnosis when there are circulating hairy cells and obvious marrow infiltration is usually straightforward. However, after effective treatment hairy cells may be extremely difficult to identify morphologically in trephine sections, and immunohistology may be very helpful in this situation. In our results, B-ly-7 and the other MoAbs identified a group of treated patients with immunohistologically reactive cells who otherwise appeared to be in complete remission by morphologic criteria. The three patients thus identified had received significantly less therapy than those in whom no cells were identified. Because B-ly-7 does not react with monocytes or normal cells that could be reactive with other MoAbs, it is possible that B-ly-7 may be superior to other anti-HCL MoAbs in the detection of residual disease. We are addressing this question with further studies. Nevertheless, our experience here, similar to that recently reported by Thaler et a1,6 suggests that immunohistology might identify patients with residual disease despite apparently normal histology.
This study has also demonstrated that the B-ly-7 antigen is present in a few cases of T-cell malignancies, including one ATLL, one Stzary, and one T-NHL. Six cases of ATLL were tested, but B-ly-7 expression was found in only one, therefore, the expression is unlikely to represent a consistent feature of the phenotype on this disease. The morphology and phenotype of this ATLL case were typical with characteristic expression of CD3, CD5, CD25, and CD4, while CD8 was absent. Three cases of (CD8+) large granular lymphocyte leukemiaI6 lacked B-ly-7 expression. The expression of B-ly-7 in mucosal associated T-cell lymphoma is recently reported'.'' (S. Poppema and L. Visser, submitted).
T and B cells were stimulated in vitro to investigate whether B-ly-7 may be an activation antigen on lymphoid cells. Previously, Visser et al' showed that a small B-cell For personal use only. on October 23, 2017. by guest www.bloodjournal.org From subset in normal peripheral blood is B-ly-7 positive, and they have also demonstrated B-ly-7 expression on TPA-stimulated, highly purified (95% CD20+) peripheral blood B cells (L. Visser and S. Poppema, submitted, 1989) . We were unable to find the B-ly-7 antigen on purified tonsillar B cells stimulated with either TPA or EBV. Expression of B-ly-7 occurred on a subset of PHA-stimulated, nonpurified peripheral blood T cells, but it was not possible to demonstrate antigen expression in purified tonsillar T cells stimulated under identical conditions. The expression of the antigen in peripheral blood T cells occurred relatively late after stimulation; ie, onset on day 3 and maximal on day 5, while the antigen was undetectable on day 1 of culture. By comparison, CD25 and HLA-DR antigens were demonstrable on the surface of these cells on day 1 of culture, indicating that the B-ly-7 antigen is independent of them and under different regulatory control. The finding that B-ly-7+ cells in PHA-stimulated normal
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From peripheral blood were predominantly CD8+ cells is of interest. Two-color analysis demonstrated that the B-ly-7 population was a subset of CD2+, CD25+ cells, accounted for most CD8+ cells, and was mutually exclusive of CD4 cells. The B-ly-7 marker may be associated with a subset of CD8 cells, a suggestion that is supported by the expression of B-ly-7 on a high proportion of intraepithelial T cells in the small bowel? These cells are CD7+, CD3+, or CD3-, and CD8+ or CD8-, and have rearrangements of the T-cell receptor y chain gene. In accordance with this finding, B-ly-7 was found to be expressed in a case of mucosal-associated T-cell lymphoma of the ileum (CD3-, C D S , CD7+) (S. Poppema and L. Visser, submitted). The appearance of this antigen on activation in a high proportion of peripheral blood CD8+ T cells as well as B cells suggests that the molecule recognized may have a common functional significance for B cells and CD8 cells.
Visser et al' have demonstrated that B-ly-7 immunoprecipitated a molecule of 144 Kd from the surface of HCL cells. It will be important to determine whether the antigen present on HCL cells and the B-ly-7 antigen now found on activated CD8+ cells is the same molecule or whether this is due to cross-reactivity. Because HCL represents an activated stage of B-cell development and the HCL-associated antigens CD25 and HC-2 have also been identified on normal activated B cells, it is likely that the B-ly-7 reactive molecule represents an activation antigen for B-cell lineage (as shown by HCL) and on CD8+ T lymphocytes.
